Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
This study is currently recruiting participants.
Verified July 2011 by Threshold Pharmaceuticals
Study NCT01403610   Information provided by Threshold Pharmaceuticals

First Received on July 22, 2011.   Last Updated on July 25, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIGH GRADE GLIOMA
Additional conditions recognized in this trial
Astrocytoma
Glioma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
TH-302
Placebo
Additional drug interventions recognized in this trial
Bevacizumab
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Threshold Pharmaceuticals
The University of Texas Health Science Center at San Antonio


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services